Non-surgical skin tightening treatments are designed for patients with mild to moderate skin laxity who want improvement without incisions, general anesthesia, or a longer recovery
By Application: T2DM dominates, Obesity growing fastest Type 2 Diabetes Mellitus maintained the dominant application position in the GLP-1 Receptor Agonist Market in 2025, driven by the large established prescriber base, comprehensive insurance coverage for diabetes indications, and the longer clinical history of GLP-1 therapy in diabetes management that has built physician comfort and treatment guideline endorsement
If it regularly dips below 32 degrees in certain spots, those spots are freezing territory, and you need to keep medication away from them
Insurance premiums are already sky-high and rising, and demand for these drugs is far more widespread than demand for a hepatitis treatment
In less than a decade, the field has progressed from single-receptor compounds (semaglutide) to dual-receptor compounds (tirzepatide) to the first triple-receptor agonist retatrutide currently in advanced clinical trials